Grant: Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Direct Payment
$41,667.00
Targeting the HER2 pathway in breast tumor-initiating cells
EF 2012-13
Résumé
Currently only breast cancer patients with HER2-positive tumors are treated with HER2-targeted therapies. However, recent clinical observations suggest that inhibiting HER2 in tumors that express low levels of HER2 may also improve survival. How inhibiting HER2 leads to beneficial effects in HER2-low breast cancer is poorly understood. I hypothesize that the HER2 pathway regulates a subset of tumor cells called cancer stem cells or tumor-initiating cells (TICs). TICs often make up only a small proportion of tumors but are the only cells that are able to divide indefinitely. Current anti-cancer therapies often leave behind a small number of resistant TICs that can cause tumor relapses and successful treatment requires the complete elimination of all TICs in a tumor. I propose that an activator of HER2 called NRG1 is produced by TICs, activates signaling through the pathway, and promotes survival and proliferation of breast TICs. If true, this would explain why anti-HER2 treatments improve survival of some patients with HER2-low tumors. I will evaluate the effect of NRG1 and HER2 inhibition in breast TICs as well as the chemo- and radiosensitizing effects. Importantly, I also plan to apply single cell-based analysis methods to surgical specimens from HER2-low breast cancer patients in order to establish what fraction of these tumors rely on the NRG1/HER2 pathway. This work will directly lead to a clinical assay that will then be used to test a personalized strategy of employing HER2 pathway inhibitors in the subset of HER2-low breast cancer patients whose TICs display pathway activity. This could significantly broaden the applicability of HER2-targeted therapy to a larger group of breast cancer patients in a personalized fashion. Thus, this proposal has a high chance of significantly impacting individual patients with breast cancer.
Programme
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
270523
Name
Lee Cleo Y
Region
California
Country
United States of America
Orgtype
Research Institution
Partnername
Breast Cancer Society of Canada (North Sarnia, ON)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting the HER2 pathway in breast tumor-initiating cells
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$41,667
Cihrequipment2
$0
Programname2
Fellowship - PA: Eileen Iwanicki Fellowships in Breast Cancer Research
Keyworddelim
Autocrine Nrg1 Signaling; Breast Cancer Stem Cell; Chemotherapy; Her2/Her3 Signaling Pathway; Radiation Thearpy
Abstract
Currently only breast cancer patients with HER2-positive tumors are treated with HER2-targeted therapies. However, recent clinical observations suggest that inhibiting HER2 in tumors that express low levels of HER2 may also improve survival. How inhibiting HER2 leads to beneficial effects in HER2-low breast cancer is poorly understood. I hypothesize that the HER2 pathway regulates a subset of tumor cells called cancer stem cells or tumor-initiating cells (TICs). TICs often make up only a small proportion of tumors but are the only cells that are able to divide indefinitely. Current anti-cancer therapies often leave behind a small number of resistant TICs that can cause tumor relapses and successful treatment requires the complete elimination of all TICs in a tumor. I propose that an activator of HER2 called NRG1 is produced by TICs, activates signaling through the pathway, and promotes survival and proliferation of breast TICs. If true, this would explain why anti-HER2 treatments improve survival of some patients with HER2-low tumors. I will evaluate the effect of NRG1 and HER2 inhibition in breast TICs as well as the chemo- and radiosensitizing effects. Importantly, I also plan to apply single cell-based analysis methods to surgical specimens from HER2-low breast cancer patients in order to establish what fraction of these tumors rely on the NRG1/HER2 pathway. This work will directly lead to a clinical assay that will then be used to test a personalized strategy of employing HER2 pathway inhibitors in the subset of HER2-low breast cancer patients whose TICs display pathway activity. This could significantly broaden the applicability of HER2-targeted therapy to a larger group of breast cancer patients in a personalized fashion. Thus, this proposal has a high chance of significantly impacting individual patients with breast cancer.
Competitiondate
201210
Approvedterm2
1 yr 8 mths
Pinamesdelim
Lee, Cleo Y
Approvedterm
1 an 8 mois
Cihrcontribution2
Breast Cancer Initiative~ $41,667~ $0~